Creative Planning cut its stake in shares of Sientra Inc (NASDAQ:SIEN) by 18.0% in the first quarter, Holdings Channel reports. The institutional investor owned 28,300 shares of the medical instruments supplier’s stock after selling 6,200 shares during the quarter. Creative Planning’s holdings in Sientra were worth $243,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Sientra during the 4th quarter valued at $29,000. Great West Life Assurance Co. Can purchased a new stake in shares of Sientra in the 4th quarter worth $64,000. Metropolitan Life Insurance Co. NY increased its stake in shares of Sientra by 356.6% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 8,191 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 6,397 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Sientra in the 4th quarter worth $135,000. Finally, HRT Financial LLC purchased a new stake in shares of Sientra in the 4th quarter worth $157,000. Institutional investors and hedge funds own 85.74% of the company’s stock.
Several equities research analysts have recently commented on the company. BidaskClub upgraded Sientra from a “strong sell” rating to a “sell” rating in a research note on Thursday, April 25th. Craig Hallum set a $23.00 price objective on Sientra and gave the stock a “buy” rating in a research note on Monday, April 22nd. Zacks Investment Research upgraded Sientra from a “sell” rating to a “hold” rating in a research note on Wednesday, April 17th. Wells Fargo & Co assumed coverage on Sientra in a research note on Thursday, March 14th. They issued a “market perform” rating and a $9.00 price objective for the company. Finally, ValuEngine lowered Sientra from a “buy” rating to a “hold” rating in a research note on Thursday, March 14th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and six have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus target price of $21.00.
Sientra (NASDAQ:SIEN) last issued its earnings results on Wednesday, May 8th. The medical instruments supplier reported ($0.91) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.15). The firm had revenue of $17.55 million during the quarter, compared to the consensus estimate of $17.00 million. Sientra had a negative return on equity of 119.59% and a negative net margin of 126.32%. Sell-side analysts expect that Sientra Inc will post -2.84 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: This story was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://www.baseballdailydigest.com/news/2019/05/13/creative-planning-decreases-holdings-in-sientra-inc-sien.html.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Recommended Story: Is the QQQ ETF safe?
Want to see what other hedge funds are holding SIEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sientra Inc (NASDAQ:SIEN).
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.